Effect of adriamycin combined with metformin on biological function of human tongue cancer SSC-15 cells

Zhang,Jun

doi:10.3892/ol.2019.10237

Effect of adriamycin combined with metformin on biological function of human tongue cancer SSC-15 cells

Authors:
- Jun Zhang
View Affiliations

Affiliations: Department of Stomatology, Qianfoshan Hospital of Shandong Province, Jinan, Shandong 250014, P.R. China
Published online on: April 10, 2019 https://doi.org/10.3892/ol.2019.10237
Pages: 5674-5680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect of adriamycin (ADM) combined with metformin (MET) on the biological function of human tongue cancer SSC-15 cells was investigated. SCC-15 cells (ATCC® CRL-1623) were cultured in vitro. The close concentration of the median lethal dose (LD50) of ADM was 0.05 mg/l and the LD50 of MET was 10 mmol/l after 48 h of intervention. They were used for drug combination experiments. Cells without drug treatment were used as the control group, cells treated with ADM alone, MET alone and their drug combination (ADM+MET) as the experimental groups. CCK-8 was used to detect the cell survival rate, and flow cytometry to detect the apoptosis rate in each group, Transwell chamber to detect the invasion ability in vitro of cells and scratch-healing experiment to observe the migration ability of the cells. The survival rate of tongue cancer SCC-15 cells gradually decreased with the increase in ADM and MET concentrations and in intervention time (P<0.05). The apoptosis rate in the ADM, MET and ADM+MET groups was significantly higher than that in the control group (P<0.05). The apoptosis rate in the ADM+MET group was higher than that in the ADM and MET groups (P<0.05). The invasion and migration ability of cells in the ADM and MET groups were higher than those in the ADM+MET group (P<0.05). The cell membrane number and the migration rate of cells in the ADM+MET group were significantly lower than those in the ADM and MET groups (P<0.05). Both MET and ADM inhibit the growth, invasion and migration of tongue cancer SSC-15 cells, and induce their apoptosis. Thus, ADM and MET in combination is more effective than ADM alone and MET alone in inhibiting the growth, invasion and migration of tongue cancer cells as well as in inducing their apoptosis.

View Figures

View References

1	He Q, Chen Z, Cabay RJ, Zhang L, Luan X, Chen D, Yu T, Wang A and Zhou X: microRNA-21 and microRNA-375 from oral cytology as biomarkers for oral tongue cancer detection. Oral Oncol. 57:15–20. 2016. View Article : Google Scholar : PubMed/NCBI
2	Liu W, Zhao X, Zhang YJ, Fang GW and Xue Y: MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 46:975–983. 2018. View Article : Google Scholar : PubMed/NCBI
3	Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009. View Article : Google Scholar : PubMed/NCBI
4	Mao L, Li J, Chen WX, Cai YQ, Yu DD, Zhong SL, Zhao JH, Zhou JW and Tang JH: Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol. 37:5247–5256. 2016. View Article : Google Scholar : PubMed/NCBI
5	Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX, Chen X, Yang SJ, Shen H, Zhong SL, Tang JH, et al: Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 37:3227–3235. 2016. View Article : Google Scholar : PubMed/NCBI
6	Dundar HA, Kiray M, Kir M, Kolatan E, Bagriyanik A, Altun Z, Aktas S, Ellidokuz H, Yilmaz O, Mutafoglu K, et al: Protective effect of acetyl-L-carnitine against doxorubicin-induced cardiotoxicity in wistar albino rats. Arch Med Res. 47:506–514. 2016. View Article : Google Scholar : PubMed/NCBI
7	McCreight LJ, Bailey CJ and Pearson ER: Metformin and the gastrointestinal tract. Diabetologia. 59:426–435. 2016. View Article : Google Scholar : PubMed/NCBI
8	Yang J, Wei D, Wang W, Shen B, Xu S and Cao Y: TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway. Int J Clin Exp Pathol. 8:11837–11846. 2015.PubMed/NCBI
9	Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G and Wei J: Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 36:204–214. 2015. View Article : Google Scholar : PubMed/NCBI
10	Wang L, Wang Z, Zhao X, Ji N, Zhou Y and Li J: The inhibitory effect of metformin on oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi. 50:360–365. 2015.(In Chinese). PubMed/NCBI
11	Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
12	Cui R, Yue W, Lattime EC, Stein MN, Xu Q and Tan XL: Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget. 7:50735–50754. 2016. View Article : Google Scholar : PubMed/NCBI
13	Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu JC, Sopka DS, Mehra R, Lango MN, Fundakowski C, Ridge JA and Galloway TJ: Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence. World J Otorhinolaryngol Head Neck Surg. 2:193–197. 2016. View Article : Google Scholar : PubMed/NCBI
15	Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB and Sun ZJ: PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 6:42067–42080. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cai WX, Yu RQ, Ma L, Huang HZ, Zheng LW and Zwahlen R: Differences between epithelial and mesenchymal human tongue cancer cell lines in experimental metastasis. Oncol Lett. 15:9959–9964. 2018.PubMed/NCBI
17	Jung HM, Benarroch Y and Chan EK: Anti-cancer drugs reactivate tumor suppressor miR-375 expression in tongue cancer cells. J Cell Biochem. 116:836–843. 2015. View Article : Google Scholar : PubMed/NCBI
18	Rogulj D, El Aklouk I, Konjevoda P, Ljubić S, Pibernik Okanović M, Barbir A, Luburić M, Radman M, Budinski N and Vučić Lovrenčić M: Age-dependent systemic DNA damage in early Type 2 Diabetes mellitus. Acta Biochim Pol. 64:233–238. 2017. View Article : Google Scholar : PubMed/NCBI
19	Merino J, Leong A, Liu CT, Porneala B, Walford GA, von Grotthuss M, Wang TJ, Flannick J, Dupuis J, Levy D, et al: Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose. Diabetologia. 61:1315–1324. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zhang J and Zhang Y, Tan X, Zhang Q, Liu C and Zhang Y: MiR-23b-3p induces the proliferation and metastasis of esophageal squamous cell carcinomas cells through the inhibition of EBF3. Acta Biochim Biophys Sin (Shanghai). 50:605–614. 2018. View Article : Google Scholar : PubMed/NCBI
22	Kabel AM, Omar MS, Balaha MF and Borg HM: Effect of metformin and adriamycin on transplantable tumor model. Tissue Cell. 47:498–505. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, et al: Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI
24	Miao L, Guo S, Lin CM, Liu Q and Huang L: Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev. 115:3–22. 2017. View Article : Google Scholar : PubMed/NCBI